Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17943275 | 0.91 | LGALS9 (0.44) | ADORA2AADORA3ADORA1LGALS9LGALS8 | |
| SCHEMBL17943262 | 0.91 | SLC28A2 (0.44) | ADORA2AADORA3ADORA1LMNAMTOR | |
| SCHEMBL17943263 | 0.90 | ADORA1 (0.42) | ADORA2AADORA3ADORA1HPGDSMN1; SMN2 | |
| SCHEMBL17943267 | 0.89 | SLC28A2 (0.44) | ADORA2AADORA1SLC28A2 | |
| SCHEMBL27093320 | 0.89 | ADORA2A (0.42) | ADORA2AADORA3ADORA1LGALS9LGALS8 | |
| SCHEMBL27093293 | 0.84 | SLC28A2 (0.44) | ADORA2AADORA3ADORA1LGALS9LGALS8 | |
| SCHEMBL17943264 | 0.84 | ADORA2A (0.43) | ADORA2AADORA3ADORA1LGALS9LGALS8 | |
| SCHEMBL17943276 | 0.84 | ADORA2A (0.43) | ADORA2ALMNAMTORTHRBMDM2 | |
| SCHEMBL27093290 | 0.83 | IDE (0.40) | ADORA2AADORA3ADORA1LGALS9LGALS8 | |
| SCHEMBL27093338 | 0.82 | GALR3 (0.44) | ADORA2AADORA3ADORA1LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160348112-A1 | Compositions and Methods for Detecting Microorganisms | SOMALOGIC OPERATING CO. INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | ADORA2A 61/4885ADORA3 54/4885ADORA1 66/4885 |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | ADORA2A 61/4885ADORA3 54/4885ADORA1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.